|
1
|
Nightingale J, Lum B, Ladwa R, Simpson F
and Panizza B: Adenoid cystic carcinoma: A review of clinical
features, treatment targets and advances in improving the immune
response to monoclonal antibody therapy. Biochim Biophys Acta Rev
Cancer. 1875:1885232021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cantù G: Adenoid cystic carcinoma. An
indolent but aggressive tumour. Part A: From aetiopathogenesis to
diagnosis. Acta Otorhinolaryngol Ital. 41:206–214. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang Z, Pan J, Chen J, Wu S, Wu T, Ye H,
Zhang H, Nie X and Huang C: Multicentre clinicopathological study
of adenoid cystic carcinoma: A report of 296 cases. Cancer Med.
10:1120–1127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Coca-Pelaz A, Rodrigo JP, Bradley PJ,
Vander Poorten V, Triantafyllou A, Hunt JL, Strojan P, Rinaldo A,
Haigentz M Jr, Takes RP, et al: Adenoid cystic carcinoma of the
head and neck-an update. Oral Oncol. 51:652–661. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fang Y, Peng Z, Wang Y, Gao K, Liu Y, Fan
R, Zhang H, Xie Z and Jiang W: Current opinions on diagnosis and
treatment of adenoid cystic carcinoma. Oral Oncol. 130:1059452022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jaso J and Malhotra R: Adenoid cystic
carcinoma. Arch Pathol Lab Med. 135:511–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dillon PM, Chakraborty S, Moskaluk CA,
Joshi PJ and Thomas CY: Adenoid cystic carcinoma: A review of
recent advances, molecular targets, and clinical trials. Head Neck.
38:620–627. 2016. View Article : Google Scholar
|
|
8
|
Seshadri M and Rich LJ: Ultrasound guided
generation of PDOX models of adenoid cystic carcinoma.
EBioMedicine. 42:382019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ha H, Keam B, Ock CY, Kim TM, Kim JH,
Chung EJ, Kwon SK, Ahn SH, Wu HG, Sung MW and Heo DS: Role of
concurrent chemoradiation on locally advanced unresectable adenoid
cystic carcinoma. Korean J Intern Med. 36:175–181. 2021. View Article : Google Scholar :
|
|
10
|
Guazzo E, Bowman J, Porceddu S, Webb L and
Panizza B: Advanced adenoid cystic carcinoma of the skull base-the
role of surgery. Oral Oncol. 99:1044662019. View Article : Google Scholar
|
|
11
|
Atallah S, Marc M, Schernberg A, Huguet F,
Wagner I, Mäkitie A and Baujat B: Beyond surgical treatment in
adenoid cystic carcinoma of the head and neck: A literature review.
Cancer Manag Res. 14:1879–1890. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fabris L, Ceder Y, Chinnaiyan AM, Jenster
GW, Sorensen KD, Tomlins S, Visakorpi T and Calin GA: The potential
of MicroRNAs as prostate cancer biomarkers. Eur Urol. 70:312–322.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krol J, Loedige I and Filipowicz W: The
widespread regulation of microRNA biogenesis, function and decay.
Nat Rev Genet. 11:597–610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen JQ, Papp G, Szodoray P and Zeher M:
The role of microRNAs in the pathogenesis of autoimmune diseases.
Autoimmun Rev. 15:1171–1180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu B, Li J and Cairns MJ: Identifying
miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014.
View Article : Google Scholar :
|
|
17
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Achkar NP, Cambiagno DA and Manavella PA:
miRNA biogenesis: A dynamic pathway. Trends Plant Sci.
21:1034–1044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hata A and Lieberman J: Dysregulation of
microRNA biogenesis and gene silencing in cancer. Sci Signal.
8:re32015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee TJ, Yuan X, Kerr K, Yoo JY, Kim DH,
Kaur B and Eltzschig HK: Strategies to modulate MicroRNA functions
for the treatment of cancer or organ injury. Pharmacol Rev.
72:639–667. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pritchard CC, Cheng HH and Tewari M:
MicroRNA profiling: Approaches and considerations. Nat Rev Genet.
13:358–369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu TX and Rothenberg ME: MicroRNA. J
Allergy Clin Immunol. 141:1202–1207. 2018. View Article : Google Scholar :
|
|
23
|
Dragomir MP, Knutsen E and Calin GA:
Classical and noncanonical functions of miRNAs in cancers. Trends
Genet. 38:379–394. 2022. View Article : Google Scholar
|
|
24
|
Hussen BM, Hidayat HJ, Salihi A, Sabir DK,
Taheri M and Ghafouri-Fard S: MicroRNA: A signature for cancer
progression. Biomed Pharmacother. 138:1115282021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kiss O, Tőkés AM, Vranic S, Gatalica Z,
Vass L, Udvarhelyi N, Szász AM and Kulka J: Expression of miRNAs in
adenoid cystic carcinomas of the breast and salivary glands.
Virchows Arch. 467:551–562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Auxzilia Preethi K, Chandralekha
Selvakumar S and Sekar D: MicroRNAs and it's targets in the
treatment of salivary adenoid cystic carcinoma. Oral Oncol.
133:1060532022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andreasen S, Tan Q, Agander TK, Hansen
TVO, Steiner P, Bjørndal K, Høgdall E, Larsen SR, Erentaite D,
Olsen CH, et al: MicroRNA dysregulation in adenoid cystic carcinoma
of the salivary gland in relation to prognosis and gene fusion
status: A cohort study. Virchows Arch. 473:329–340. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mitani Y, Roberts DB, Fatani H, Weber RS,
Kies MS, Lippman SM and El-Naggar AK: MicroRNA profiling of
salivary adenoid cystic carcinoma: Association of miR-17-92
upregulation with poor outcome. PLoS One. 8:e667782013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Brown AL, Al-Samadi A, Sperandio M, Soares
AB, Teixeira LN, Martinez EF, Demasi APD, Araújo VC, Leivo I, Salo
T and Passador-Santos F: MiR-455-3p miR-150 and miR-375 are
aberrantly expressed in salivary gland adenoid cystic carcinoma and
polymorphous adenocarcinoma. J Oral Pathol Med. 48:840–845. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao J, Liu X, Lin J, Jiang M, Xu F, Zhang
C, Tang Q, Zhu L, Dong L and Lin T: AKT2 identified as a potential
target of mir-29a-3p via microRNA profiling of patients with high
proliferation lacrimal gland adenoid cystic carcinoma. Exp Eye Res.
219:1090672022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang HD, Jiang LH, Sun DW, Li J and Ji
ZL: The role of miR-130a in cancer. Breast Cancer. 24:521–527.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Yan D, Wu W, Zhu J, Ye W and Shu
Q: MicroRNA-130a promotes the metastasis and epithelial-mesenchymal
transition of osteosarcoma by targeting PTEN. Oncol Rep.
35:3285–3292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang XC, Tian LL, Wu HL, Jiang XY, Du LQ,
Zhang H, Wang YY, Wu HY, Li DG, She Y, et al: Expression of
miRNA-130a in nonsmall cell lung cancer. Am J Med Sci. 340:385–388.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sand M, Skrygan M, Sand D, Georgas D, Hahn
SA, Gambichler T, Altmeyer P and Bechara FG: Expression of
microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishihara K, Sasaki D, Tsuruda K, Inokuchi
N, Nagai K, Hasegawa H, Yanagihara K and Kamihira S: Impact of
miR-155 and miR-126 as novel biomarkers on the assessment of
disease progression and prognosis in adult T-cell leukemia. Cancer
Epidemiol. 36:560–565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang H, Yu WW, Wang LL and Peng Y:
miR-130a acts as a potential diagnostic biomarker and promotes
gastric cancer migration, invasion and proliferation by targeting
RUNX3. Oncol Rep. 34:1153–1161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kovaleva V, Mora R, Park YJ, Plass C,
Chiramel AI, Bartenschlager R, Döhner H, Stilgenbauer S, Pscherer
A, Lichter P and Seiffert M: miRNA-130a targets ATG2B and DICER1 to
inhibit autophagy and trigger killing of chronic lymphocytic
leukemia cells. Cancer Res. 72:1763–1772. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Boll K, Reiche K, Kasack K, Mörbt N,
Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn
F and Hackermüller J: MiR-130a, miR-203 and miR-205 jointly repress
key oncogenic pathways and are downregulated in prostate carcinoma.
Oncogene. 32:277–285. 2013. View Article : Google Scholar
|
|
41
|
Qiu S, Lin S, Hu D, Feng Y, Tan Y and Peng
Y: Interactions of miR-323/miR-326/miR-329 and
miR-130a/miR-155/miR-210 as prognostic indicators for clinical
outcome of glioblastoma patients. J Transl Med. 11:102013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li B, Huang P, Qiu J, Liao Y, Hong J and
Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma
and associates with poor prognosis. Med Oncol. 31:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang X, Huang L, Zhao Y and Tan W:
Downregulation of miR-130a contributes to cisplatin resistance in
ovarian cancer cells by targeting X-linked inhibitor of apoptosis
(XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 45:995–1001.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long
G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion
and migration in human breast cancer by targeting the RAB5A. Int J
Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
|
|
45
|
He L, Wang HY, Zhang L, Huang L, Li JD,
Xiong Y, Zhang MY, Jia WH, Yun JP, Luo RZ and Zheng M: Prognostic
significance of low DICER expression regulated by miR-130a in
cervical cancer. Cell Death Dis. 5:e12052014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ramsay RG and Gonda TJ: MYB function in
normal and cancer cells. Nat Rev Cancer. 8:523–534. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim G, Lim S and Kim KD: N-myc
downstream-regulated gene 2 (NDRG2) function as a positive
regulator of apoptosis: A new insight into NDRG2 as a tumor
suppressor. Cells. 10:26492021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Zhang CY, Xia RH, Han J, Sun B,
Sun SY and Li J: The MYB/miR-130a/NDRG2 axis modulates tumor
proliferation and metastatic potential in salivary adenoid cystic
carcinoma. Cell Death Dis. 9:9172018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li YF, Jing Y, Hao J, Frankfort NC, Zhou
X, Shen B, Liu X, Wang L and Li R: MicroRNA-21 in the pathogenesis
of acute kidney injury. Protein Cell. 4:813–819. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bautista-Sánchez D, Arriaga-Canon C,
Pedroza-Torres A, De La Rosa-Velázquez IA, González-Barrios R,
Contreras-Espinosa L, Montiel-Manríquez R, Castro-Hernández C,
Fragoso-Ontiveros V, Álvarez-Gómez RM and Herrera LA: The promising
role of miR-21 as a cancer biomarker and its importance in
RNA-based therapeutics. Mol Ther Nucleic Acids. 20:409–420. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Das PK, Islam F and Lam AK: The roles of
cancer stem cells and therapy resistance in colorectal carcinoma.
Cells. 9:13922020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Dioguardi M, Caloro GA, Laino L, Alovisi
M, Sovereto D, Crincoli V, Aiuto R, Coccia E, Troiano G and Lo
Muzio L: Circulating miR-21 as a potential biomarker for the
diagnosis of oral cancer: A systematic review with meta-analysis.
Cancers (Basel). 12:9362020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ribas J and Lupold SE: The transcriptional
regulation of miR-21, its multiple transcripts, and their
implication in prostate cancer. Cell Cycle. 9:923–929. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li S, Yang X, Yang J, Zhen J and Zhang D:
Serum microRNA-21 as a potential diagnostic biomarker for breast
cancer: A systematic review and meta-analysis. Clin Exp Med.
16:29–35. 2016. View Article : Google Scholar
|
|
55
|
Jiang LH, Ge MH, Hou XX, Cao J, Hu SS, Lu
XX, Han J, Wu YC, Liu X, Zhu X, et al: miR-21 regulates tumor
progression through the miR-21-PDCD4-Stat3 pathway in human
salivary adenoid cystic carcinoma. Lab Invest. 95:1398–1408. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang C, Li T, Yan F, Cai W, Zheng J, Jiang
X and Sun J: Effect of simvastatin and microRNA-21 inhibitor on
metastasis and progression of human salivary adenoid cystic
carcinoma. Biomed Pharmacother. 105:1054–1061. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H
and Yang W: Simvastatin induced ferroptosis for triple-negative
breast cancer therapy. J Nanobiotechnology. 19:3112021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen MC, Tsai YC, Tseng JH, Liou JJ, Horng
S, Wen HC, Fan YC, Zhong WB and Hsu SP: Simvastatin inhibits cell
proliferation and migration in human anaplastic thyroid cancer. Int
J Mol Sci. 18:26902017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yu X, Pan Y, Ma H and Li W: Simvastatin
inhibits proliferation and induces apoptosis in human lung cancer
cells. Oncol Res. 20:351–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yan F, Wang C, Li T, Cai W and Sun J: Role
of miR-21 in the growth and metastasis of human salivary adenoid
cystic carcinoma. Mol Med Rep. 17:4237–4244. 2018.PubMed/NCBI
|
|
61
|
Chen X, Chen S, Xiu YL, Sun KX, Zong ZH
and Zhao Y: RhoC is a major target of microRNA-93-5P in epithelial
ovarian carcinoma tumorigenesis and progression. Mol Cancer.
14:312015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen X, Liu J, Zhang Q, Liu B, Cheng Y,
Zhang Y, Sun Y, Ge H and Liu Y: Exosome-mediated transfer of
miR-93-5p from cancer-associated fibroblasts confer radioresistance
in colorectal cancer cells by downregulating FOXA1 and upregulating
TGFB3. J Exp Clin Cancer Res. 39:652020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ma DH, Li BS, Liu JJ, Xiao YF, Yong X,
Wang SM, Wu YY, Zhu HB, Wang DX and Yang SM: miR-93-5p/IFNAR1 axis
promotes gastric cancer metastasis through activating the STAT3
signaling pathway. Cancer Lett. 408:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shi X, Liu TT, Yu XN, Balakrishnan A, Zhu
HR, Guo HY, Zhang GC, Bilegsaikhan E, Sun JL, Song GQ, et al:
microRNA-93-5p promotes hepatocellular carcinoma progression via a
microRNA-93-5p/MAP3K2/c-Jun positive feedback circuit. Oncogene.
39:5768–5781. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gong C, Qu S, Lv XB, Liu B, Tan W, Nie Y,
Su F, Liu Q, Yao H and Song E: BRMS1L suppresses breast cancer
metastasis by inducing epigenetic silence of FZD10. Nat Commun.
5:54062014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Koyama R, Tamura M, Nakagaki T, Ohashi T,
Idogawa M, Suzuki H, Tokino T and Sasaki Y: Identification and
characterization of a metastatic suppressor BRMS1L as a target gene
of p53. Cancer Sci. 108:2413–2421. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Hao J, Jin X, Shi Y and Zhang H: miR-93-5p
enhance lacrimal gland adenoid cystic carcinoma cell tumorigenesis
by targeting BRMS1L. Cancer Cell Int. 18:722018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sun Z, Zhang Q, Yuan W, Li X, Chen C, Guo
Y, Shao B, Dang Q, Zhou Q, Wang Q, et al: MiR-103a-3p promotes
tumour glycolysis in colorectal cancer via hippo/YAP1/HIF1A axis. J
Exp Clin Cancer Res. 39:2502020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Fu M, Chen CW, Yang LQ, Yang WW, Du ZH, Li
YR, Li SL and Ge XY: MicroRNA-103a-3p promotes metastasis by
targeting TPD52 in salivary adenoid cystic carcinoma. Int J Oncol.
57:574–586. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Shehata M, Bièche I, Boutros R,
Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK,
Lidereau R and Byrne JA: Nonredundant functions for tumor protein
D52-like proteins support specific targeting of TPD52. Clin Cancer
Res. 14:5050–5060. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Rubin MA, Varambally S, Beroukhim R,
Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M,
Kuefer R, Fletcher JA, et al: Overexpression, amplification, and
androgen regulation of TPD52 in prostate cancer. Cancer Res.
64:3814–3822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang SJ, Li YJ, Gao B, Li XL, Li YT and He
HY: Long non-coding RNA 00152 slicing represses the growth and
aggressiveness of hemangioma cell by modulating miR-139-5p. Biomed
Pharmacother. 120:1093852019. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tennstedt P, Bölch C, Strobel G, Minner S,
Burkhardt L, Grob T, Masser S, Sauter G, Schlomm T and Simon R:
Patterns of TPD52 overexpression in multiple human solid tumor
types analyzed by quantitative PCR. Int J Oncol. 44:609–615. 2014.
View Article : Google Scholar
|
|
74
|
Ravegnini G, Cargnin S, Sammarini G,
Zanotti F, Bermejo JL, Hrelia P, Terrazzino S and Angelini S:
Prognostic role of miR-221 and miR-222 expression in cancer
patients: A systematic review and meta-analysis. Cancers (Basel).
11:9702019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Song J, Ouyang Y, Che J, Li X, Zhao Y,
Yang K, Zhao X, Chen Y, Fan C and Yuan W: Potential value of
miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers
for diseases. Front Immunol. 8:562017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Jiang F, Zhao W, Zhou L, Zhang L, Liu Z
and Yu D: miR-222 regulates the cell biological behavior of oral
squamous cell carcinoma by targeting PUMA. Oncol Rep. 31:1255–1262.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhou Z, Zhou L, Jiang F, Zeng B, Wei C,
Zhao W and Yu D: Downregulation of miR-222 induces apoptosis and
cellular migration in adenoid cystic carcinoma cells. Oncol Res.
25:207–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sperka T, Wang J and Rudolph KL: DNA
damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol
Cell Biol. 13:579–590. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Li Y, He Y, Xiang J, Feng L, Wang Y and
Chen R: The functional mechanism of MicroRNA in oral lichen planus.
J Inflamm Res. 15:4261–4274. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li Y, Tian Z, Tan Y, Lian G, Chen S, Chen
S, Li J, Li X, Huang K and Chen Y: Bmi-1-induced miR-27a and
miR-155 promote tumor metastasis and chemoresistance by targeting
RKIP in gastric cancer. Mol Cancer. 19:1092020. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Van Roosbroeck K, Fanini F, Setoyama T,
Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I,
Redis RS, D'Abundo L, et al: Combining anti-Mir-155 with
chemotherapy for the treatment of lung cancers. Clin Cancer Res.
23:2891–2904. 2017. View Article : Google Scholar
|
|
82
|
Kulkarni P, Dasgupta P, Hashimoto Y,
Shiina M, Shahryari V, Tabatabai ZL, Yamamura S, Tanaka Y, Saini S,
Dahiya R and Majid S: A lncRNA TCL6-miR-155 interaction regulates
the Src-Akt-EMT network to mediate kidney cancer progression and
metastasis. Cancer Res. 81:1500–1512. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bacci M, Giannoni E, Fearns A, Ribas R,
Gao Q, Taddei ML, Pintus G, Dowsett M, Isacke CM, Martin LA, et al:
miR-155 drives metabolic reprogramming of ER+ breast cancer cells
following long-term estrogen deprivation and predicts clinical
response to aromatase inhibitors. Cancer Res. 76:1615–1626. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hess AK, Müer A, Mairinger FD, Weichert W,
Stenzinger A, Hummel M, Budach V and Tinhofer I: MiR-200b and
miR-155 as predictive biomarkers for the efficacy of chemoradiation
in locally advanced head and neck squamous cell carcinoma. Eur J
Cancer. 77:3–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Gulei D, Raduly L, Broseghini E, Ferracin
M and Berindan-Neagoe I: The extensive role of miR-155 in malignant
and non-malignant diseases. Mol Aspects Med. 70:33–56. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Liu L, Hu Y, Fu J, Yang X and Zhang Z:
MicroRNA155 in the growth and invasion of salivary adenoid cystic
carcinoma. J Oral Pathol Med. 42:140–147. 2013. View Article : Google Scholar
|
|
87
|
Biswas DK and Iglehart JD: Linkage between
EGFR family receptors and nuclear factor kappaB (NF-kappaB)
signaling in breast cancer. J Cell Physiol. 209:645–652. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cascinu S, Verdecchia L, Valeri N, Berardi
R and Scartozzi M: New target therapies in advanced pancreatic
cancer. Ann Oncol. 17(Suppl 5): v148–v152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Bianco R, Gelardi T, Damiano V, Ciardiello
F and Tortora G: Rational bases for the development of EGFR
inhibitors for cancer treatment. Int J Biochem Cell Biol.
39:1416–1431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Feng X, Matsuo K, Zhang T, Hu Y, Mays AC,
Browne JD, Zhou X and Sullivan CA: MicroRNA profiling and target
genes related to metastasis of salivary adenoid cystic carcinoma.
Anticancer Res. 37:3473–3481. 2017.PubMed/NCBI
|
|
91
|
Jin Y, Chen X, Gao ZY, Liu K, Hou Y and
Zheng J: The role of miR-320a and IL-1β in human chondrocyte
degradation. Bone Joint Res. 6:196–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shang C, Zhang H, Guo Y, Hong Y, Liu Y and
Xue Y: MiR-320a down-regulation mediates bladder carcinoma invasion
by targeting ITGB3. Mol Biol Rep. 41:2521–2527. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Xie N, Jia Z and Li L: miR-320a
upregulation contributes to the development of preeclampsia by
inhibiting the growth and invasion of trophoblast cells by
targeting interleukin 4. Mol Med Rep. 20:3256–3264. 2019.PubMed/NCBI
|
|
94
|
Lv G, Wu M, Wang M, Jiang X, Du J, Zhang
K, Li D, Ma N, Peng Y, Wang L, et al: miR-320a regulates high
mobility group box 1 expression and inhibits invasion and
metastasis in hepatocellular carcinoma. Liver Int. 37:1354–1364.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhang L, Chen H, He F, Zhang S, Li A and
Zhang A and Zhang A: MicroRNA-320a promotes epithelial ovarian
cancer cell proliferation and invasion by targeting RASSF8. Front
Oncol. 11:5819322021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Sun L, Liu B, Lin Z, Yao Y, Chen Y, Li Y,
Chen J, Yu D, Tang Z, Wang B, et al: MiR-320a acts as a prognostic
factor and inhibits metastasis of salivary adenoid cystic carcinoma
by targeting ITGB3. Mol Cancer. 14:962015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Fuentes P, Sesé M, Guijarro PJ, Emperador
M, Sánchez-Redondo S, Peinado H, Hümmer S, Ramón Y and Cajal S:
ITGB3-mediated uptake of small extracellular vesicles facilitates
intercellular communication in breast cancer cells. Nat Commun.
11:42612020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zheng ZQ, Li ZX, Zhou GQ, Lin L, Zhang LL,
Lv JW, Huang XD, Liu RQ, Chen F, He XJ, et al: Long noncoding RNA
FAM225A promotes nasopharyngeal carcinoma tumorigenesis and
metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and
upregulate ITGB3. Cancer Res. 79:4612–4626. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Zhao B, Han H, Chen J, Zhang Z, Li S, Fang
F, Zheng Q, Ma Y, Zhang J, Wu N and Yang Y: MicroRNA let-7c
inhibits migration and invasion of human non-small cell lung cancer
by targeting ITGB3 and MAP4K3. Cancer Lett. 342:43–51. 2014.
View Article : Google Scholar
|
|
101
|
Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y,
Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the
proliferation, migration and invasion of gastric cancer by
regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Rothman AM, Arnold ND, Pickworth JA,
Iremonger J, Ciuclan L, Allen RM, Guth-Gundel S, Southwood M,
Morrell NW, Thomas M, et al: MicroRNA-140-5p and SMURF1 regulate
pulmonary arterial hypertension. J Clin Invest. 126:2495–2508.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Kelly RJ, Lopez-Chavez A, Citrin D, Janik
JE and Morris JC: Impacting tumor cell-fate by targeting the
inhibitor of apoptosis protein survivin. Mol Cancer. 10:352011.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Martínez-García D, Manero-Rupérez N,
Quesada R, Korrodi-Gregório L and Soto-Cerrato V: Therapeutic
strategies involving survivin inhibition in cancer. Med Res Rev.
39:887–909. 2019. View Article : Google Scholar
|
|
105
|
Qiao Z, Zou Y and Zhao H: MicroRNA-140-5p
inhibits salivary adenoid cystic carcinoma progression and
metastasis via targeting survivin. Cancer Cell Int. 19:3012019.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Peng W, Sha H, Sun X, Zou R, Zhu Y, Zhou G
and Feng J: Role and mechanism of miR-187 in human cancer. Am J
Transl Res. 12:4873–4884. 2020.PubMed/NCBI
|
|
107
|
Mulrane L, Madden SF, Brennan DJ, Gremel
G, McGee SF, McNally S, Martin F, Crown JP, Jirström K, Higgins DG,
et al: miR-187 is an independent prognostic factor in breast cancer
and confers increased invasive potential in vitro. Clin Cancer Res.
18:6702–6713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Chao A, Lin CY, Lee YS, Tsai CL, Wei PC,
Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, et al: Regulation of
ovarian cancer progression by microRNA-187 through targeting
disabled homolog-2. Oncogene. 31:764–775. 2012. View Article : Google Scholar
|
|
109
|
Liang Z, Xu J, Ma Z, Li G and Zhu W:
MiR-187 suppresses non-small-cell lung cancer cell proliferation by
targeting FGF9. Bioengineered. 11:70–80. 2020. View Article : Google Scholar :
|
|
110
|
Bagaeva LV, Rao P, Powers JM and Segal BM:
CXC chemokine ligand 13 plays a role in experimental autoimmune
encephalomyelitis. J Immunol. 176:7676–7685. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Hussain M, Adah D, Tariq M, Lu Y, Zhang J
and Liu J: CXCL13/CXCR5 signaling axis in cancer. Life Sci.
227:175–186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Zhang M, Wu JS, Xian HC, Chen BJ, Wang HF,
Yu XH, Pang X, Dai L, Jiang J, Liang XH and Tang YL: CXCR5 induces
perineural invasion of salivary adenoid cystic carcinoma by
inhibiting microRNA-187. Aging (Albany NY). 13:15384–15399. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Gui T and Shen K: miRNA-101: A potential
target for tumor therapy. Cancer Epidemiol. 36:537–540. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Liang H, Yu T, Han Y, Jiang H, Wang C, You
T, Zhao X, Shan H, Yang R, Yang L, et al: LncRNA PTAR promotes EMT
and invasion-metastasis in serous ovarian cancer by competitively
binding miR-101-3p to regulate ZEB1 expression. Mol Cancer.
17:1192018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li
C, Kang P, Leng K, Ji D, Li Z, et al: SP1-induced upregulation of
lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding
EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J
Exp Clin Cancer Res. 37:812018. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Cao S, Lin L, Xia X and Wu H: lncRNA
SPRY4-IT1 regulates cell proliferation and migration by sponging
miR-101-3p and regulating AMPK expression in gastric cancer. Mol
Ther Nucleic Acids. 17:455–464. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zhang X, Gao D, Fang K, Guo Z and Li L:
Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer
progression by regulating the EGFR/MEK/ERK signaling pathway.
Cancer Lett. 444:105–115. 2019. View Article : Google Scholar
|
|
118
|
Liu D, Li Y, Luo G, Xiao X, Tao D, Wu X,
Wang M, Huang C, Wang L, Zeng F and Jiang G: LncRNA SPRY4-IT1
sponges miR-101-3p to promote proliferation and metastasis of
bladder cancer cells through up-regulating EZH2. Cancer Lett.
388:281–291. 2017. View Article : Google Scholar
|
|
119
|
Xu J, Xiong G, Cao Z, Huang H, Wang T, You
L, Zhou L, Zheng L, Hu Y, Zhang T and Zhao Y: PIM-1 contributes to
the malignancy of pancreatic cancer and displays diagnostic and
prognostic value. J Exp Clin Cancer Res. 35:1332016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pang W, Tian X, Bai F, Han R, Wang J, Shen
H, Zhang X, Liu Y, Yan X, Jiang F and Xing L: Pim-1 kinase is a
target of miR-486-5p and eukaryotic translation initiation factor
4E, and plays a critical role in lung cancer. Mol Cancer.
13:2402014. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Liu XY, Liu ZJ, He H, Zhang C and Wang YL:
MicroRNA-101-3p suppresses cell proliferation, invasion and
enhances chemotherapeutic sensitivity in salivary gland adenoid
cystic carcinoma by targeting Pim-1. Am J Cancer Res. 5:3015–3029.
2015.PubMed/NCBI
|
|
122
|
Zhou H, Huang Z, Chen X and Chen S: miR-98
inhibits expression of TWIST to prevent progression of non-small
cell lung cancers. Biomed Pharmacother. 89:1453–1461. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Huang SD, Yuan Y, Zhuang CW, Li BL, Gong
DJ, Wang SG, Zeng ZY and Cheng HZ: MicroRNA-98 and microRNA-214
post-transcriptionally regulate enhancer of zeste homolog 2 and
inhibit migration and invasion in human esophageal squamous cell
carcinoma. Mol Cancer. 11:512012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Liu X, Zhang W, Guo H, Yue J and Zhuo S:
miR-98 functions as a tumor suppressor in salivary adenoid cystic
carcinomas. Onco Targets Ther. 9:1777–1786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Thumar J, Shahbazian D, Aziz SA, Jilaveanu
LB and Kluger HM: MEK targeting in N-RAS mutated metastatic
melanoma. Mol Cancer. 13:452014. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Wang Y, Velho S, Vakiani E, Peng S, Bass
AJ, Chu GC, Gierut J, Bugni JM, Der CJ, Philips M, et al: Mutant
N-RAS protects colorectal cancer cells from stress-induced
apoptosis and contributes to cancer development and progression.
Cancer Discov. 3:294–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Bhatlekar S, Manne BK, Basak I, Edelstein
LC, Tugolukova E, Stoller ML, Cody MJ, Morley SC, Nagalla S,
Weyrich AS, et al: miR-125a-5p regulates megakaryocyte proplatelet
formation via the actin-bundling protein L-plastin. Blood.
136:1760–1772. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Nishida N, Mimori K, Fabbri M, Yokobori T,
Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M:
MicroRNA-125a-5p is an independent prognostic factor in gastric
cancer and inhibits the proliferation of human gastric cancer cells
in combination with trastuzumab. Clin Cancer Res. 17:2725–2733.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Liu X, Zhao T, Yuan Z and Ge S: MIR600HG
sponges miR-125a-5p to regulate glycometabolism and cisplatin
resistance of oral squamous cell carcinoma cells via mediating
RNF44. Cell Death Discov. 8:2162022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Falcicchia C, Tozzi F, Arancio O,
Watterson DM and Origlia N: Involvement of p38 MAPK in synaptic
function and dysfunction. Int J Mol Sci. 21:56242020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Han J and Sun P: The pathways to tumor
suppression via route p38. Trends Biochem Sci. 32:364–371. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Liang Y, Ye J, Jiao J, Zhang J, Lu Y,
Zhang L, Wan D, Duan L, Wu Y and Zhang B: Down-regulation of
miR-125a-5p is associated with salivary adenoid cystic carcinoma
progression via targeting p38/JNK/ERK signal pathway. Am J Transl
Res. 9:1101–1113. 2017.PubMed/NCBI
|
|
134
|
Zeng X, Ma X, Guo H, Wei L, Zhang Y, Sun
C, Han N, Sun S and Zhang N: MicroRNA-582-5p promotes
triple-negative breast cancer invasion and metastasis by
antagonizing CMTM8. Bioengineered. 12:10126–10135. 2021. View Article : Google Scholar
|
|
135
|
Han B, Bhowmick N, Qu Y, Chung S, Giuliano
AE and Cui X: FOXC1: An emerging marker and therapeutic target for
cancer. Oncogene. 36:3957–3963. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Gilding LN and Somervaille TCP: The
diverse consequences of FOXC1 deregulation in cancer. Cancers
(Basel). 11:1842019. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Wang WW, Chen B, Lei CB, Liu GX, Wang YG,
Yi C, Wang YY and Zhang SY: miR-582-5p inhibits invasion and
migration of salivary adenoid cystic carcinoma cells by targeting
FOXC1. Jpn J Clin Oncol. 47:690–698. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Xie H, Tang J, Lu L, Li B and Wang M:
CASC9 plays a role in salivary adenoid cystic carcinoma in vitro by
upregulation of ACLY. Oral Dis. 28:352–363. 2022. View Article : Google Scholar
|
|
139
|
Huo F, Zhang C, He H and Wang Y:
MicroRNA-144-3p inhibits proliferation and induces apoptosis of
human salivary adenoid carcinoma cells via targeting of mTOR.
Biotechnol Lett. 38:409–416. 2016. View Article : Google Scholar
|
|
140
|
Hou CX, Sun NN, Han W, Meng Y, Wang CX,
Zhu QH, Tang YT and Ye JH: Exosomal microRNA-23b-3p promotes tumor
angiogenesis and metastasis by targeting PTEN in salivary adenoid
cystic carcinoma. Carcinogenesis. 43:682–692. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Li Z, Zhang Q, Su H, Li HY, Cao G, Xu JK,
Wang JL, Niu CZ, Zhang F, Yang J and Chen W: miR-5191 acts as a
tumor suppressor in salivary adenoid cystic carcinoma by targeting
Notch-2. Oral Dis. 28:1871–1881. 2022. View Article : Google Scholar
|
|
142
|
Wang S, Zhang L, Shi P, Zhang Y, Zhou H
and Cao X: Genome-wide profiles of metastasis-associated mRNAs and
microRNAs in salivary adenoid cystic carcinoma. Biochem Biophys Res
Commun. 500:632–638. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Xie S, Yu X, Li Y, Ma H, Fan S, Chen W,
Pan G, Wang W, Zhang H, Li J and Lin Z: Upregulation of lncRNA
ADAMTS9-AS2 promotes salivary adenoid cystic carcinoma metastasis
via PI3K/Akt and MEK/Erk signaling. Mol Ther. 26:2766–2778. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ju R, Huang Y, Guo Z, Han L, Ji S, Zhao L
and Long J: The circular RNAs differential expression profiles in
the metastasis of salivary adenoid cystic carcinoma cells. Mol Cell
Biochem. 476:1269–1282. 2021. View Article : Google Scholar
|
|
147
|
Xu Q, Liu X, Chen W and Zhang Z:
Inhibiting adenoid cystic carcinoma cells growth and metastasis by
blocking the expression of ADAM 10 using RNA interference. J Transl
Med. 8:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Andreasen S: Molecular features of adenoid
cystic carcinoma with an emphasis on microRNA expression. Apmis.
126(Suppl 140): S7–S57. 2018. View Article : Google Scholar
|
|
149
|
Liang H, Gong F, Zhang S, Zhang CY, Zen K
and Chen X: The origin, function, and diagnostic potential of
extracellular microRNAs in human body fluids. Wiley Interdiscip Rev
RNA. 5:285–300. 2014. View Article : Google Scholar
|
|
150
|
Papaspyrou G, Hoch S, Rinaldo A, Rodrigo
JP, Takes RP, van Herpen C, Werner JA and Ferlito A: Chemotherapy
and targeted therapy in adenoid cystic carcinoma of the head and
neck: A review. Head Neck. 33:905–911. 2011. View Article : Google Scholar
|
|
151
|
Le Tourneau C, Razak AR, Levy C, Calugaru
V, Galatoire O, Dendale R, Desjardins L and Gan HK: Role of
chemotherapy and molecularly targeted agents in the treatment of
adenoid cystic carcinoma of the lacrimal gland. Br J Ophthalmol.
95:1483–1489. 2011. View Article : Google Scholar
|
